Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
Cottereau AS, Buvat I, Kanoun S, Versari A, Casasnovas O, Chauvie S, et al. Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma? Eur J Nucl Med Mol Imaging. 2018;45(8):1463–4.CrossRef
2.
Ilyas H, Mikhaeel NG, Dunn JT, Rahman F, Møller H, Smith D, Barrington SF. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142–54.CrossRef
3.
Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella A, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Fingerle-Rowson G, Knapp A, Mattiello F, Nielsen T, Sellam G, Sahin D, Vitolo U, Trněný M. Baseline PET-derived metabolic tumor volume metrics predict progression-free and overall survival in DLBCL after first-line treatment: results from the phase 3 GOYA study. Blood. 2017.
4.
Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large b-cell lymphoma. J Clin Oncol. 2017;35:3529–37.CrossRef
5.
Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma. PLoS One. 2015;10:e0140830.CrossRef
6.
Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22.CrossRef
Metadata
Title
Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?
Authors
Hajira Ilyas
N. George Mikhaeel
Joel T. Dunn
Fareen Rahman
Henrik Möller
Daniel Smith
Sally F. Barrington
Publication date
01-02-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-018-4200-3

Other articles of this Issue 2/2019

European Journal of Nuclear Medicine and Molecular Imaging 2/2019 Go to the issue

Original Article

Myocardial MIBG scintigraphy in genetic Parkinson’s disease as a model for Lewy body disorders

Original Article

Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes

Original Article

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease

Original Article

Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer

Original Article

Nicotinic receptor abnormalities as a biomarker in idiopathic generalized epilepsy

Society Communications

First steps in an uncharted territory by WFNMB